1. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial;Hurvitz;Lancet Oncol,2015
2. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2–overexpressing locally advanced breast cancers;Dave;J Clin Oncol,2011
3. Preclinical testing of clinically applicable strategies for overcoming herceptin resistance caused by PTEN deficiency;Lu;Clin Cancer Res,2007
4. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial;André;Lancet Oncol,2014
5. Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: combined exploratory analysis from BOLERO-1 and BOLERO-3;Slamon;Proc Am Soc Clin Oncol,2015